Evidence map›Paper›PMID 39878501›Full record

ArticleEpigenomics2025

EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines.

Maryam Latarani, Perla Pucci, Mark Eccleston, Massimiliano Manzo, Priyadarsini Gangadharannambiar, Irene Fischetti, Ilaria Alborelli, Vera Mongiardini, Namra Mahmood, Mario Paolo Colombo and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epigenomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Maryam LataraniCancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK.
Perla PucciDivision of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK.
Mark EcclestonBelgian Volition SPRL, Parc Scientifique Créalys, Namur, BE, Belgium.ORCID 0000-0001-8496-3389
Massimiliano ManzoPathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Priyadarsini GangadharannambiarCancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK.
Irene FischettiMolecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0009-0002-3946-6388
Ilaria AlborelliPathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Vera MongiardiniMolecular Medicine Research Line, Fondazione Istituto Italiano di Tecnologia (IIT), Genoa, Italy.ORCID 0000-0002-8019-6327
Namra MahmoodCancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK.
Mario Paolo ColomboMolecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Benedetto GrimaldiMolecular Medicine Research Line, Fondazione Istituto Italiano di Tecnologia (IIT), Genoa, Italy.ORCID 0000-0002-2589-9302
Sushila RigasCancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK.
Shusuke AkamatsuDepartment of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Cheryl HawkesDivision of Biomedical and Life Sciences, Lancaster University, Lancaster, UK.
Yuzhuo WangDepartment of Experimental Therapeutics, BC Cancer/University of British Columbia, Vancouver, Canada.ORCID 0000-0002-9749-8591
Elena JachettiMolecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Francesco CreaCancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK.ORCID 0000-0002-4903-2973

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAggressive Variant Prostate Cancers (AVPCs) are incurable malignancies. Platinum-based chemotherapies are used for the palliative treatment of AVPC. The Polycomb Repressive Complex 2 (PRC2) promotes prostate cancer progression

methodsWe studied the expression of PRC2 genes in clinical prostate cancer cohorts (bioinformatics). We determined the effect of EZH2i on cellular- and cf-H3K27me3 levels. We measured dose-dependent effects of Carboplatin with/without EZH2i on AVPC cell viability (IC

resultsPRC2 genes were significantly up-regulated in AVPC

conclusionsEZH2i plus Carboplatin is a promising combination treatment for AVPC.

Indexed as

Antineoplastic AgentsCarboplatinEnhancer of Zeste Homolog 2 ProteinProstatic NeoplasmsCell Line, TumorEpigenesis, GeneticGene Expression Regulation, NeoplasticHistonesHumansMaleAntineoplastic AgentsCarboplatinEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanHistonesaggressive variant prostate cancerCarboplatinepigeneticsEZH2neuroendocrine prostate cancerpersonalized epigenetic therapiesTazemetostat

Identifiers

PMID39878501
PMCPMC11812314

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.